BRIEF — Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China

Oct 13 (Reuters) — Wuhan Hiteck Biological Pharma Co Ltd: Wuhan Hiteck Biological Pharma Co - Grants Visara Exclusive Rights To Ht006.2.2 Outside Greater China Wuhan Hiteck Biological Pharma Co - To Receive Upfront Payment, Milestone Payments, And Tiered Royalties Wuhan Hiteck Biological Pharma Co - Phase 1b Study Shows 50% Complete Corneal Healing In Highest Dose Cohort After 8 Weeks Wuhan Hiteck Biological Pharma Co - Treatment-related Ocular Adverse Events Were Mild With No Study Withdrawals Source text:... Further company coverage: 300683.SZ (Reuters.Briefs@thomsonreuters.com;)